Different doses or strenghts? [General Sta­tis­tics]

posted by Dr_Dan  – Germany, 2013-11-21 16:23 (4597 d 16:06 ago) – Posting: # 11937
Views: 10,357

Dear kumarnaidu
You are talking about a two period cross-over study with 4 treatments, right?
I am not a statistician but I guess it would be reasonable to divide R also into 3 groups with 5 subjects each so that you have an intra-individual comparison T1 vs R1, T2 vs R2 and T3 vs R3. If possible I would prefer a 4 way cross over design, three times test one reference with 5 subjects each.
Bioequivalence: Two medicinal products are bioequivalent if they are pharmaceutically equivalent and if their bioavailabilities after administration in the same molar dose are similar to such degree that their effects, with respect to both efficacy and safety, will be essentially the same. I guess in your case we are talking about comparative bioavailabilities and the test products are no pure generic formulations, right?
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
153 visitors (0 registered, 153 guests [including 19 identified bots]).
Forum time: 09:30 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5